window.pageData = {"stock":{"_id":3000000024819,"name":"中欧医药生物混合型发起式证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"024819","tickerId":24819,"shortName":"中欧医药生物混合发起C","currency":"CNY","exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"inceptionDate":"2025-11-27T16:00:00.000Z","pinyin":"zoyyswhhxfqszqtzjj","fundCollectionId":4000050570000,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50570000","tickerId":50570000,"name":"中欧基金管理有限公司"},"managers":[{"name":"赵磊","stockType":"fund_manager","stockCode":"8801640678","exchange":"fm","tickerId":2612250950}],"hotMetrics":{"fpr":{"stockId":3000000024819,"type":"fpr","f_cagr_p_r_fs_ssc":9177,"f_cagr_p_r_fs_ssrp":0.9629468177855275,"f_p_r_fys_ssc":8989,"f_p_r_fys_ssrp":0.9101023587004895,"f_p_r_m1_ssc":9236,"f_p_r_m1_ssrp":0.954737412019491,"f_p_r_m3_ssc":9128,"f_p_r_m3_ssrp":0.8113290237756108},"fp":{"stockId":3000000024819,"type":"fp","last_data_date":"2026-05-20T16:00:00.000Z","f_p_r_fys":-0.05682634116319596,"f_p_r_m1":-0.0735516372795968,"f_cagr_p_r_fs":-0.08077576726981872,"f_p_r_m3":-0.05264784669276712},"ff":{"stockId":3000000024819,"type":"ff","f_fr_d":"2026-05-19T16:00:00.000Z","f_m_fr":0.012,"f_c_fr":0.002,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000024819,"type":"f_nlacan","f_nv_d":"2026-05-20T16:00:00.000Z","f_nv":0.9195,"f_nv_cr":0.014228987425545903},"f_as":{"stockId":3000000024819,"type":"f_as","f_tas":329573.5632,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000024818,"__csrcFundId":16090,"stockCode":"024818","masterFundShortName":"中欧医药生物混合发起","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":24818,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"中欧医药生物混合发起(024818)","lastUpdated":"2026-05-01T04:25:59.302Z","name":"中欧医药生物混合型发起式证券投资基金","pinyin":"zoyyswhhxfqszqtzjj","fundCollectionId":4000050570000,"setUpAssetScale":10453213.86,"setUpDate":"2025-11-25T16:00:00.000Z","setUpShares":10453213.86,"inceptionDate":"2025-11-27T16:00:00.000Z","followedNum":4}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":603259,"holdings":11400,"marketCap":1118340,"netValueRatio":0.0981,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":2821,"holdings":9600,"marketCap":1063392,"netValueRatio":0.0933,"quarterlyChange":0.19197245238351623,"stock":{"stockCode":"002821","exchange":"sz","stockType":"company","tickerId":2821,"name":"凯莱英"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":600276,"holdings":13200,"marketCap":728904,"netValueRatio":0.064,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":300759,"holdings":20500,"marketCap":573590,"netValueRatio":0.0503,"quarterlyChange":-0.015828350334153862,"stock":{"stockCode":"300759","exchange":"sz","stockType":"company","tickerId":300759,"name":"康龙化成"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":1000000000002269,"holdings":19000,"marketCap":553945,"netValueRatio":0.0486,"quarterlyChange":0.05025445292620789,"stock":{"stockCode":"02269","exchange":"hk","stockType":"company","tickerId":2269,"name":"药明生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":1000000000009926,"holdings":4000,"marketCap":459840,"netValueRatio":0.0404,"quarterlyChange":0.1522123893805305,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":1000000000001530,"holdings":23000,"marketCap":459769,"netValueRatio":0.0403,"quarterlyChange":-0.06368899917286963,"stock":{"stockCode":"01530","exchange":"hk","stockType":"company","tickerId":1530,"name":"三生制药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":2653,"holdings":7800,"marketCap":423384,"netValueRatio":0.0372,"quarterlyChange":0.057677318784099096,"stock":{"stockCode":"002653","exchange":"sz","stockType":"company","tickerId":2653,"name":"海思科"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":300347,"holdings":7800,"marketCap":419874,"netValueRatio":0.0368,"quarterlyChange":-0.050617283950616376,"stock":{"stockCode":"300347","exchange":"sz","stockType":"company","tickerId":300347,"name":"泰格医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","fundId":3000000024818,"stockId":688180,"holdings":11307,"marketCap":393822,"netValueRatio":0.0346,"quarterlyChange":0.01961358313817363,"stock":{"stockCode":"688180","tickerId":688180,"exchange":"sh","stockType":"company","name":"君实生物"}}]},"list":[{"_id":"69e8eca81398d79843fea087","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-21T16:00:00.000Z","stockId":3000000024818,"sao":"2026年一季度中证生物医药指数下跌3.77%，表现略强于同期下跌3.89%的沪深300指数。医药板块内呈现明显分化和快速轮动的态势，创新产业链、脑机接口、AI医疗、地缘政治受益线等各有表现。从细分板块看，创新产业链涨幅靠前，化学制药、医疗器械、生物制品板块阶段性表现突出，中药表现相对稳健，医药商业承压。  中国创新药行业正逐步成长为具备全球竞争力的支柱行业，龙头企业的研发能力和产品质量获得全球认可，近年来中国创新药对外授权交易规模显著增长。同时，医保资金对创新药的支付也在持续扩大，预计未来有望进一步增加。  创新产业链行业确定性加强。全球经历新冠疫情后的低潮期，创新研发投入增速回归到正常水平。国内头部公司凭借运营服务能力，进一步证明相较竞争对手的优势，短期份额被抢占的风险较低。同时，在减肥药、小核酸等市场预期规模百亿美元以上的细分领域，中国企业在供应链中占据主要地位。近两年来订单表现突出，部分环节价格回升，预计未来几年有望看到报表持续修复。  医疗器械产业逐步完成产品力积累，进口替代、国际化逐步推进，同时可以观察到手术机器人、脑机接口等新兴方向在政策催化、技术突破、资本加持背景下实现快速的产业化进程。  医疗服务、中药等消费领域，行业基本面角度观察到逐步改善的迹象，龙头公司有望凭借运营和品牌优势率先实现温和复苏。  本基金目前保持较高仓位运作。如上所述，投资策略聚焦在增量，重点寻找能够获取更大份额的细分领域。  虽然外部宏观环境依然复杂，地缘政治扰动，国内医保改革持续推进，但对医药行业的中长期价值保持乐观。本基金通过重点布局相关行业，希望为投资人获得长期投资收益。","lastUpdated":"2026-04-22T15:43:36.385Z","fund":{"_id":3000000024818,"__csrcFundId":16090,"stockCode":"024818","masterFundShortName":"中欧医药生物混合发起","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":24818,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"中欧医药生物混合发起(024818)","lastUpdated":"2026-05-01T04:25:59.302Z","name":"中欧医药生物混合型发起式证券投资基金","pinyin":"zoyyswhhxfqszqtzjj","fundCollectionId":4000050570000,"setUpAssetScale":10453213.86,"setUpDate":"2025-11-25T16:00:00.000Z","setUpShares":10453213.86,"inceptionDate":"2025-11-27T16:00:00.000Z","followedNum":4,"managers":[{"stockCode":"8801640678","stockType":"fund_manager","exchange":"fm","tickerId":2612250950,"name":"赵磊"}]},"announcement":{"linkText":"中欧医药生物混合型发起式证券投资基金2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1477950","linkType":"PDF","source":"csrc_pdf"}}]}